Beyond Legacy Tools: Defining Modern AI Drug Discovery for 2025 and Beyond
Curating Biological Findings from Scientific Literature with NVIDIA NIM
How top pharma companies boost efficacy
CytoReason’s proven artificial intelligence-powered disease models and analytics platform are providing insights at scale. The probability of technical and regulatory success (PTRS) in drug development is around 8%1. The highest impact is the 36% probability of success in phase 2, impacted by limited efficacy. To increase efficacy success and thereby patient health and commercial outcomes, […]
Digital Health 50: The most promising digital health startups of 2024
Making Clinical Trials Better for Everyone in 2023
Roundtable: What do you view as the most disruptive or transformational technology or development on the horizon?
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances
Technology diffusion strategies for CIOs and the VC mindset
Sanofi extends cooperation with Israel’s CytoReason for bowel disease drug discovery
Follow the Money: University of Chicago Funds Biotech Accelerator, Breakthrough Tankless Inhaled Nitric Oxide Delivery System, More
